In this phase @ randomised study of safety and observational study of efficacy , patients with HCV genotype @ infection and chronic kidney disease ( stage @-@ with or without haemodialysis dependence ) were randomly assigned to receive grazoprevir ( @ mg , NS@/@A protease inhibitor ) and elbasvir ( @ mg , NS@A inhibitor ; immediate treatment group ) or placebo ( deferred treatment group ) once daily for @ weeks .